<DOC>
	<DOC>NCT01345656</DOC>
	<brief_summary>A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally</brief_summary>
	<brief_title>BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Men aged 18 years and older or postmenopausal women aged 55 years and older or women aged 18 years and older without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy Clinical diagnosis of CHF (chronic heart failure), either ischemic or nonischemic, NYHA (New York Heart Association) class II III, treated with evidencedbased therapy for CHF, e.g. betablockers and ACE (angiotensinconverting enzyme) inhibitors or ARB (angiotensin receptor blocker) as well as diuretics, unless contraindicated or not tolerated Known kidney damage for &gt;/= 3 months, as defined by structural or functional abnormalities of the kidney, and Part A: 60 mL/min/1.73 m2 &lt;/= eGFR (estimated Glomerular Filtration Rate) &lt; 90 mL/min/1.73 m2 (MDRD, Modification of Diet in Renal Disease) at the screening visit Part B: 30 mL/min/1.73 m2 &lt;/= eGFR &lt;= 60 mL/min/1.73 m2 (MDRD) at the screening visit Serum potassium &lt;/= 4.8 mmol/L at the screening visit Systolic blood pressure &gt;/= 90 mmHg without signs or symptoms of hypotension at the screening visit Known hypersensitivity to the study drug (active substance or excipients) or spironolactone and respective excipients (Part B only) Subjects with anuria, acute renal failure, or Addison's disease Acute coronary syndrome or unstable coronary artery disease within 30 days prior to randomization Valvular heart disease requiring surgical intervention during the course of the study History of hospitalization for hyperkalemia or acute renal failure induced by previous aldosterone antagonist treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Heart Failure</keyword>
</DOC>